The FDA published new guidance establishing an approval framework for personalized gene editing treatments that could benefit different patient subsets with the same disease, creating a 'plug and play' pathway to accelerate individualized therapies.
Three major research institutions announced the creation of the Center for Therapeutic Genetics, a nonprofit collaboration aimed at developing standardized genetic medicines, including base and prime editing, for rare and ultra-rare diseases that currently lack treatments.
The Advanced Research Projects Agency for Health (ARPA-H) has launched a $160 million initiative to fund seven groups over five years to develop custom gene editing drugs, aiming to replicate successes like the Baby KJ case.
Dr. Swee Lay Thein and Dr. Stuart Orkin received the $3 million Breakthrough Prize in Life Sciences for research that led to the development of the first CRISPR-based therapy for sickle cell disease.